The Scientist

» Duchenne muscular dystrophy

Most Recent

image: Conditional FDA Approval for Fatal-Disease Drug

Conditional FDA Approval for Fatal-Disease Drug

By | September 19, 2016

The agency OKs Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy through its accelerated approval pathway, which requires a confirmatory clinical trial.

0 Comments

image: Another Fatal-Disease Drug in Limbo

Another Fatal-Disease Drug in Limbo

By | April 26, 2016

A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.

0 Comments

image: First Data from Anti-Aging Gene Therapy

First Data from Anti-Aging Gene Therapy

By | April 25, 2016

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

8 Comments

image: CRISPR Improves Disease in Adult Mice

CRISPR Improves Disease in Adult Mice

By | January 4, 2016

Three groups of researchers used the gene-editing method to restore a protein deficient in Duchenne muscular dystrophy.

1 Comment

image: CRISPR Therapy in a Dish

CRISPR Therapy in a Dish

By | December 8, 2015

Redirecting the gene-editing tool to modulate gene expression, researchers restore protein function in cells from a child with Duchenne muscular dystrophy.

1 Comment

image: Fatal-Disease Drug in Limbo

Fatal-Disease Drug in Limbo

By | November 25, 2015

A panel of experts advised the US Food and Drug Administration that BioMarin Pharmaceutical has not demonstrated efficacy of its new drug for Duchenne muscular dystrophy.

0 Comments

image: (Re)Programming Director

(Re)Programming Director

By | October 1, 2012

Unwilling to accept the finality of terminal differentiation, Helen Blau has honed techniques that showcase the flexibility of cells to adopt different identities.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech